Related Experiment Video
Updated: Feb 7, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in
Afua A Mensah1, Luciano Cascione1,2,3, Eugenio Gaudio1
1Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Abstract:
Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors such as OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in hematologic tumors. MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p. Analysis of publicly available chromatin immunoprecipitation sequencing data of diffuse large B-cell lymphoma cells treated with bromodomain and extra-terminal domain (BET) inhibitors showed that the BET family member BRD4 bound to the upstream regulatory regions of multiple microRNA genes and that this binding decreased following BET inhibition. Alignment of our microRNA profiling data with the BRD4 chromatin immunoprecipitation sequencing data revealed that microRNAs downregulated by OTX015 also exhibited reduced BRD4 binding in their promoter regions following treatment with another bromodomain and extra-terminal domain inhibitor, JQ1, indicating that BRD4 contributes directly to microRNA expression in lymphoma. Treatment with bromodomain and extra-terminal domain inhibitors also decreased the expression of the arginine methyltransferase PRMT5, which plays a crucial role in B-cell transformation and negatively modulates the transcription of miR-96-5p. The data presented here indicate that in addition to previously observed effects on the expression of coding genes, bromodomain and extra-terminal domain inhibitors also modulate the expression of microRNAs involved in lymphomagenesis.
Insights
Bromodomain and extra-terminal domain (BET) inhibitors, like OTX015, alter microRNA expression in lymphoma cells. These inhibitors directly impact microRNA genes by reducing BRD4 binding, offering new therapeutic strategies for lymphomagenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant microRNA expression is implicated in lymphomagenesis.
- Bromodomain and extra-terminal domain (BET) inhibitors show promise in treating hematologic malignancies.
- OTX015 is a BET inhibitor with demonstrated preclinical and clinical activity.
Purpose of the Study:
- To investigate the impact of OTX015 on microRNA expression in diffuse large B-cell lymphoma (DLBCL).
- To elucidate the role of BRD4 in regulating microRNA expression in DLBCL.
- To explore the relationship between BET inhibition, PRMT5, and microRNA modulation in lymphoma.
Main Methods:
- MicroRNA profiling of DLBCL cells treated with OTX015.
- Analysis of publicly available chromatin immunoprecipitation sequencing (ChIP-seq) data for BRD4 binding in DLBCL cells.
- Correlation analysis between microRNA expression changes and BRD4 binding patterns following BET inhibition.
Main Results:
- OTX015 treatment altered the expression of specific microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p, and miR-96-5p.
- BET inhibitors, including OTX015 and JQ1, reduced BRD4 binding to microRNA regulatory regions.
- Downregulated microRNAs showed decreased BRD4 binding, suggesting direct transcriptional regulation by BRD4.
- BET inhibitor treatment also decreased PRMT5 expression, which negatively regulates miR-96-5p transcription.
Conclusions:
- BET inhibitors directly modulate microRNA expression in lymphoma by influencing BRD4 binding to microRNA gene promoters.
- The findings reveal a novel mechanism by which BET inhibitors impact lymphomagenesis through microRNA regulation.
- These results suggest that targeting BRD4 and its downstream microRNA effects could be a viable therapeutic strategy for lymphoma.
Related Concept Videos
MicroRNAs
MicroRNAs
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Termination of Translation
Diffusion
Feedback Inhibition

